Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.60
+0.33 (6.26%)
At close: May 12, 2025, 4:00 PM
5.77
+0.17 (3.04%)
After-hours: May 12, 2025, 6:49 PM EDT
Abeona Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Abeona Therapeutics stock ranges from a low of $15 to a high of $21. The average price target of $18 forecasts a 221.43% increase in the stock price over the next year.
Price Target: $18.00 (+221.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abeona Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +257.14% | Apr 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Mar 24, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $16 | Buy | Initiates | $16 | +185.71% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
12.53M
Revenue Next Year
80.18M
from 12.53M
Increased by 539.93%
EPS This Year
-0.31
from -1.55
EPS Next Year
-0.19
from -0.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 111.8M | 230.4M | ||
| Avg | 12.5M | 80.2M | 157.8M | ||
| Low | 8.8M | 55.9M | 93.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 792.6% | 187.3% | ||
| Avg | - | 539.9% | 96.8% | ||
| Low | - | 345.8% | 16.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.86 | -0.08 | 1.54 | ||
| Avg | -0.31 | -0.19 | 0.40 | ||
| Low | -1.41 | -0.41 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.